Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerl...

2020-08-24 09:14 6354

Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SUZHOU, China, Aug. 21, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered Bispecific Antibody - BCMA x CD3 (HBM7020) at the Cell engager Summit. HBM7020 was develo...

2020-08-21 21:31 6972

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

MUMBAI, India, Aug. 21, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General ofIndia (DCGI) for the launch of Stempeucel® in India. The...

2020-08-21 06:00 9250

Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen

HANGZHOU and SHAOXING, China, Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC co...

2020-08-20 20:00 3728

Sihuan Pharmaceutical Introduced Investors for Capital Increase to Accelerate Solid-liquid Double Chamber Infusion Soft Bag Industry

HONG KONG, Aug. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Beijing Ruiye Drugs Manufacture Co., Ltd. ("Beijing Ruiye"), an associate of the Grou...

2020-08-20 19:39 13722

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (forme...

2020-08-20 08:35 8517

Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market with its Expanded Portfolio and Geographic Presence

Jamjoom Pharmaceuticals is dedicated to being a center of excellence in healthcare and providing high-quality, safe, and effective products to meet the regional need JEDDAH, Saudi Arabia, Aug. 19, 2020 /PRNewswire/ -- Based on its recent analysis of the KSA emerging generic pharmaceuticals marke...

2020-08-19 16:00 1906

Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market with its Expanded Portfolio and Geographic Presence

Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement

SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2020-08-18 18:30 6076

WuXi Biologics Records Excellent Interim Results

Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to RMB736.1 Million Adjusted Net Profit Up 40.7% Y-o-Y to RMB734.0 Million Diluted EPS Up 55.9% Y-o-Y to RMB0.53 Adjusted Diluted EPS Up 38.5% Y-o-Y to RMB...

2020-08-18 00:51 2812

Start of bridging pharmacokinetic and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator O304

STOCKHOLM, Aug. 17, 2020 /PRNewswire/ -- In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was administered as a suspension and with limited oral bioavailability. A novel formulation of O304 has now been ...

2020-08-17 22:13 2426

First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU, China and SHAOXING, China, Aug. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody. ASC22(Envafolimab) Phase IIa clin...

2020-08-17 08:30 3636

Sai Life Sciences opens new, state-of-the-art Research & Technology Centre in Hyderabad

HYDERABAD, India, Aug. 17, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs) , today announced the inauguration of its new Rese...

2020-08-17 08:00 3558

Sai Life Sciences opens new, state-of-the-art Research & Technology Centre in Hyderabad

China's First Trastuzumab Biosimilar Approved by NMPA

SHANGHAI, Aug. 17, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced onAugust 14 that the trastuzumab biosimilar HLX02, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). On 27th July, HLX02 (EU bran...

2020-08-17 08:00 3960

Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

SUZHOU, China, and ROCKVILLE, MD., Aug. 17, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has been s...

2020-08-17 07:30 2853

Memo Therapeutics AG and Northway Biotechpharma Collaborate on the Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for the Therapy of COVID-19

SCHLIEREN, Switzerland and VILNIUS, Lithuania, Aug. 15, 2020 /PRNewswire/ -- Swiss biotech companyMemo Therapeutics AG (MTx) and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership to manufacture MTx...

2020-08-15 08:36 4516

Sinopharm Tech plans to purchase 337 tons Meltblown Fabric

HONG KONG, August 14, 2020 /PRNewswire/ -- Sinopharm Tech Holdings Limited ("Sinopharm Tech" and its subsidiaries, together, the "Group", stock code: 8156) is pleased to announce that, as of 13 August, 2020, the subsidiary of the Group has entered into product sales agreements with a branch of Pe...

2020-08-14 09:18 4371

Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates

SHANGHAI and SAN FRANCISCO, Aug. 13, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced financial results for the six months ended June 30, 2020 and corporate updates. "This year we have continued to build Zai Lab's lead...

2020-08-13 22:38 6605

AGC Biologics Enters into Partnership as a CDMO with Ono Pharmaceuticals to Manufacture Biopharmaceuticals at Clinical Development Stage

SEATTLE, Aug. 13, 2020 /PRNewswire/ -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with Ono Pharmaceutical Co., Ltd. (ONO) to manufacture new, innovative biopharmaceuticals at the clinical development stage. ONO...

2020-08-13 21:00 4618

ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast Track Designation for Recurrent and Metastatic Cervical Cancer

LOS ANGELES, Aug. 13, 2020 /PRNewswire/ -- Akeso, Inc (9926.HK) - a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide - today announced that the U.S. Food and Drug Admini...

2020-08-13 20:07 5240

Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility

WETTEREN, Belgium, Aug. 13, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a major expansion of small molecule manufacturing capabilities with the addition of a ...

2020-08-13 20:06 3174

1 ... 147 148 149150151 152 153 ... 181